Given the association of low PSGL-1 expression with the presence of clinical characteristics such as Raynaud ́s phenomenon or lung disease (Figure 1) and the contribution of PSGL-1/P-selectin interaction in the control of NET generation, that we describe in the present paper, both PSGL-1 and P-selectin should be further studied as potential targets for new SLE therapeutic strategies. The gene discussed is SELPLG; the disease is systemic lupus erythematosus.